Market Cap 50.02M
Revenue (ttm) 0.00
Net Income (ttm) -83.74M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.08
Volume 34,900
Avg Vol 40,214
Day's Range N/A - N/A
Shares Out 7.32M
Stochastic %K 87%
Beta 0.56
Analysts Hold
Price Target $6.00

Company Profile

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. It is also developing KZR-261,...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 822 5600
Address:
4000 Shoreline Court, Suite 300, South San Francisco, United States
floateli
floateli Feb. 20 at 3:49 PM
$KZR Kezar Life Sciences develops autoimmune and inflammatory disease therapies. Valuation is driven by clinical milestones. Cash runway defines downside risk.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 19 at 11:31 AM
$KZR RSI: 72.62, MACD: 0.0427 Vol: 0.12, MA20: 6.20, MA50: 6.24 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 19 at 12:36 AM
$KZR RSI: 72.62, MACD: 0.0427 Vol: 0.12, MA20: 6.20, MA50: 6.24 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SystematicVanguard
SystematicVanguard Feb. 18 at 4:50 PM
$KZR Kezar Life Sciences develops autoimmune therapies. Clinical milestones drive valuation. Development risk remains elevated.
0 · Reply
RoboAdvisorView
RoboAdvisorView Feb. 17 at 12:18 PM
$KZR Pre-revenue biotech; early-stage immunology pipeline.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 5 at 9:53 PM
$KZR RSI: 34.55, MACD: -0.0424 Vol: 0.09, MA20: 6.17, MA50: 6.23 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
NVDAMillionaire
NVDAMillionaire Feb. 4 at 5:43 PM
$KZR Really good write-up that perfectly summarizes KZR's present situation. So if you want to bring your KZR knowledge up to date or just discover KZR, this is required reading. https://everyticker.com/quote/KZR/analysis/kezar-life-sciences-when-a-pipeline-in-a-drug-becomes-a-strategic-dead-end-nasdaq-kzr
0 · Reply
Love_To_Learn
Love_To_Learn Jan. 20 at 12:27 PM
$KZR a bit early settle down !
0 · Reply
DARKP00L
DARKP00L Jan. 9 at 11:11 AM
$KZR 06:04 on Jan. 09 2026 Kezar Life Sciences Granted FDA Type C Meeting In Q1 To Discuss Zetomipzomib Development And Potential Global Randomized Phase 2b Study In Relapsed And Refractory Autoimmune Hepatitis #tradeideas
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 30 at 1:01 AM
$KZR Share Price: $6.34 Contract Selected: Jul 17, 2026 $10 Calls Buy Zone: $0.31 – $0.38 Target Zone: $0.56 – $0.68 Potential Upside: 72% ROI Time to Expiration: 199 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Latest News on KZR
Kezar Life Sciences Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 4:01 PM EST - 3 months ago

Kezar Life Sciences Reports Third Quarter 2025 Financial Results


Kezar Life Sciences Announces 1-for-10 Reverse Stock Split

Oct 28, 2024, 8:30 AM EDT - 1 year ago

Kezar Life Sciences Announces 1-for-10 Reverse Stock Split


Kezar Life Sciences halts mid-stage trial for lupus treatment

Sep 30, 2024, 8:46 AM EDT - 1 year ago

Kezar Life Sciences halts mid-stage trial for lupus treatment


Kezar Life Sciences to Host Virtual R&D Day on March 22, 2023

Mar 6, 2023, 7:00 AM EST - 3 years ago

Kezar Life Sciences to Host Virtual R&D Day on March 22, 2023


floateli
floateli Feb. 20 at 3:49 PM
$KZR Kezar Life Sciences develops autoimmune and inflammatory disease therapies. Valuation is driven by clinical milestones. Cash runway defines downside risk.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 19 at 11:31 AM
$KZR RSI: 72.62, MACD: 0.0427 Vol: 0.12, MA20: 6.20, MA50: 6.24 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 19 at 12:36 AM
$KZR RSI: 72.62, MACD: 0.0427 Vol: 0.12, MA20: 6.20, MA50: 6.24 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SystematicVanguard
SystematicVanguard Feb. 18 at 4:50 PM
$KZR Kezar Life Sciences develops autoimmune therapies. Clinical milestones drive valuation. Development risk remains elevated.
0 · Reply
RoboAdvisorView
RoboAdvisorView Feb. 17 at 12:18 PM
$KZR Pre-revenue biotech; early-stage immunology pipeline.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 5 at 9:53 PM
$KZR RSI: 34.55, MACD: -0.0424 Vol: 0.09, MA20: 6.17, MA50: 6.23 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
NVDAMillionaire
NVDAMillionaire Feb. 4 at 5:43 PM
$KZR Really good write-up that perfectly summarizes KZR's present situation. So if you want to bring your KZR knowledge up to date or just discover KZR, this is required reading. https://everyticker.com/quote/KZR/analysis/kezar-life-sciences-when-a-pipeline-in-a-drug-becomes-a-strategic-dead-end-nasdaq-kzr
0 · Reply
Love_To_Learn
Love_To_Learn Jan. 20 at 12:27 PM
$KZR a bit early settle down !
0 · Reply
DARKP00L
DARKP00L Jan. 9 at 11:11 AM
$KZR 06:04 on Jan. 09 2026 Kezar Life Sciences Granted FDA Type C Meeting In Q1 To Discuss Zetomipzomib Development And Potential Global Randomized Phase 2b Study In Relapsed And Refractory Autoimmune Hepatitis #tradeideas
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 30 at 1:01 AM
$KZR Share Price: $6.34 Contract Selected: Jul 17, 2026 $10 Calls Buy Zone: $0.31 – $0.38 Target Zone: $0.56 – $0.68 Potential Upside: 72% ROI Time to Expiration: 199 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Love_To_Learn
Love_To_Learn Dec. 24 at 4:57 PM
$KZR NEED TO SHUFFLE 14.7 MILLION SHARES ON U OFF THE BOOKS
0 · Reply
Adrianople117
Adrianople117 Nov. 17 at 5:49 AM
$KZR Well there goes 500k shares... cant sell 500k at once otherwise it would collapse the stock. Wait for more fomr 13s to come out this week.
0 · Reply
d_risk
d_risk Nov. 12 at 10:28 PM
$KZR - Kezar Life Sciences, Inc. - 10Q - Updated Risk Factors KZR’s latest 10-Q risk factors expand on capital needs, clinical trial and regulatory hurdles, strategic alternatives, restructuring uncertainties, IP and patent challenges, executive retention, cybersecurity, global volatility, concentrated ownership, and new compliance and anti-takeover risks. #Biotechnology #Cybersecurity #CapitalNeeds #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/KZR/10-Q/2025-11-12
0 · Reply
Adrianople117
Adrianople117 Nov. 7 at 9:58 PM
$KZR possibly.... we will see with earnings how much cash they have now.
0 · Reply
Maddmike
Maddmike Nov. 7 at 9:06 PM
$KZR back to$5 🤔
0 · Reply
Adrianople117
Adrianople117 Nov. 4 at 6:28 PM
$KZR hmmm....
0 · Reply
Adrianople117
Adrianople117 Oct. 31 at 4:27 AM
$KZR hmmm.... first its ever dropped below 6... well have to see during market open what happens... curious
0 · Reply
brj1323
brj1323 Oct. 24 at 5:20 PM
$KZR adding some here
0 · Reply
Adrianople117
Adrianople117 Oct. 21 at 1:46 AM
$KZR alot of sell orders and price hasnt dropped. Usually means institutions selling. Stock is at 6.09 after hours. My opinion we will see 4 bucks in less than a couple weeks. Sure they had 90.1 m in sept but another clinical trial re do is expensive. And they burn 4m a month without the clinical trial costs.
0 · Reply
Raxothus
Raxothus Oct. 20 at 7:48 PM
EOD CONTINUATION FOLLOW-UP – 10/17/25 Tracking continuation watchlist from yesterday based on intraday highs vs. close ❌ $SPAI – Dropped from 9.00 to 7.38 (–18%), full fade after strong prior session. Failed continuation. ⚠️ $KZR – Moving sideways, no clear trend. Neutral. ✅ $DMRC – Closed 8.60, hit HOD 9.27 (+7.8%), solid continuation with controlled pullback. ✅ $SGHT – Closed 4.60, reached 5.14 (+11.7%), clean follow-through, strong intraday action. ✅ $VANI – Closed 1.70, now 1.83 (+7.6%), gradual continuation move. Recap: 5 total → 3 winners ($DMRC, $SGHT, $VANI), 1 fail ($SPAI), 1 neutral → 60% accuracy Leaders: $SGHT showed strongest continuation, $DMRC and $VANI held structure well; $SPAI was the only full fade. #vwap #smallcaps #daytrading #eodfollowup #continuation #snipersetup #accountability
0 · Reply
topstockalerts
topstockalerts Oct. 20 at 12:00 PM
$KZR where's it going once market opens?
0 · Reply